#	Pagina
attuale pagina	/open-h2020/projects/198901/index.html
-1	/open-h2020/per-topic/popularisation/list/index.html

Opendata, web and dolomites

CYTOPRO

Profiling of tumour cells in blood for personalized treatment of metastatic cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CYTOPRO project word cloud

Explore the words cloud of the CYTOPRO project. It provides you a very rough idea of what is the project "CYTOPRO" about.

larger circulating market 2m 7bn tumour breakthrough patients markets vasculature clinical 10 form isolation 12 fail patient therapy lose annually profile 18 42 40 platform assays device solution 43bn 9 lives tool approaching first primary cells exact productivity challenge accurate citizens days individual efficient 126bn reduce incl innovation isolate lost biased deaths ctcs metastatic blood labs treatment cell superior 2013 ctc circulate losses technologies prepare routine cytotrack cancer perfect worth 6bn characterisation 3 10bn clinicians worldwide trials fast pathologists detection personalised foothold metastasised gaining 5bn diagnostic diagnosed breast customers alone regulatory mutation 2009 medicine cheap single expects gt shed bloodstream

Project "CYTOPRO" data sheet

The following table provides information about the project.

Coordinator	CYTOTRACK APS Organization address address: GAMMEL LUNDTOFTEVEJ 1D city: LYNGBY postcode: 2800 website: www.cytotrack.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Project website	http://www.cytotrack.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-10-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CYTOTRACK APS CYTOTRACK APS Organization address address: GAMMEL LUNDTOFTEVEJ 1D city: LYNGBY postcode: 2800 website: www.cytotrack.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (LYNGBY)	coordinator	50˙000.00

Map

Project objective

Challenge Up to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment. Cancer cost the EU €126bn in 2009 incl. productivity losses of €42.6bn and lost working days worth €9.43bn. 3.2m citizens in EU lose their lives to cancer each year.

Solution Circulating Tumour Cells (CTC) are cells that have shed into the vasculature from a primary tumour and circulate in the bloodstream. CytoTrack has developed a breakthrough technology that can identify and isolate metastatic cancer cells from a blood sample. It is superior to all other technologies due to a very efficient and non-biased detection principle and an integrated feature to isolate individual cells for characterisation. It is the perfect tool to be used together with new single cell characterisation assays currently being introduced on the market.

Impact The innovation will provide an effective, accurate, fast and cheap characterisation of CTCs in a single device, enabling pathologists and clinicians worldwide to deliver personalised medicine and cancer treatment targeted the exact mutation of the individual patient’s cancer form. CytoTrack expects that the innovation can reduce cancer deaths by 10%. In EU alone this would reduce the productivity loss with >€10bn per year and treatment costs with >€12.5bn.

Project This phase 1 project will investigate 1) collaboration with labs, 2) regulatory conditions for first markets, and 3) prepare for clinical trials. The overall innovation project will enable CytoTrack to be the first on the market to offer an integrated diagnostic platform for routine isolation and characterisation of metastatic cancer cells in blood, enabling personalised therapy targeting the exact profile of the cancer form.

Customers and market The CTC technology market was $3.7bn in 2013, growing 18.9% annually. The research market is a first step in gaining a strong foothold before approaching the much larger, but also more challenging, clinical market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYTOPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYTOPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination